Tokyo Tape
Sign in
← Carna Biosciences

Annual report

4572.TEDINET S100XSFK
Period2025-01-01 → 2025-12-31
Filed2026-03-26
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 133
MetricValuePeriodScopeSource row
Revenue¥579m2025-01-01 → 2025-12-31Cons.Net sales
Revenue¥636m2024-01-01 → 2024-12-31Cons.Net sales
Revenue¥1.6bn2023-01-01 → 2023-12-31vCons.Net sales (5-year summary)
Revenue¥1.4bn2022-01-01 → 2022-12-31vCons.Net sales (5-year summary)
Revenue¥2.0bn2021-01-01 → 2021-12-31dCons.Net sales (5-year summary)
Operating income−¥2.1bn2025-01-01 → 2025-12-31Cons.Operating income
Operating income−¥2.1bn2024-01-01 → 2024-12-31Cons.Operating income
Ordinary income−¥2.1bn2025-01-01 → 2025-12-31Cons.Ordinary income
Ordinary income−¥2.1bn2024-01-01 → 2024-12-31Cons.Ordinary income
Ordinary income−¥1.1bn2023-01-01 → 2023-12-31vCons.Ordinary income loss (5-year summary)
Ordinary income−¥1.3bn2022-01-01 → 2022-12-31vCons.Ordinary income loss (5-year summary)
Ordinary income−¥523m2021-01-01 → 2021-12-31dCons.Ordinary income loss (5-year summary)
Profit before tax−¥2.2bn2025-01-01 → 2025-12-31Cons.Income before income taxes
Profit before tax−¥2.2bn2024-01-01 → 2024-12-31Cons.Income before income taxes
Net income (owners)−¥2.2bn2025-01-01 → 2025-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥2.2bn2024-01-01 → 2024-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥1.2bn2023-01-01 → 2023-12-31vCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥1.3bn2022-01-01 → 2022-12-31vCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥534m2021-01-01 → 2021-12-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income−¥2.2bn2025-01-01 → 2025-12-31Cons.Profit loss
Net income−¥2.2bn2024-01-01 → 2024-12-31Cons.Profit loss
Total assets¥1.2bnat 2025-12-31Cons.Assets
Total assets¥2.8bnat 2024-12-31Cons.Assets
Total assets¥4.3bnat 2023-12-31vCons.Total assets (5-year summary)
Total assets¥4.3bnat 2022-12-31vCons.Total assets (5-year summary)
Total assets¥5.4bnat 2021-12-31dCons.Total assets (5-year summary)
Total liabilities¥920mat 2025-12-31Cons.Liabilities
Total liabilities¥297mat 2024-12-31Cons.Liabilities
Net assets / equity¥309mat 2025-12-31Cons.Net assets
Net assets / equity¥2.5bnat 2024-12-31Cons.Net assets
Net assets / equity¥3.9bnat 2023-12-31vCons.Net assets
Net assets / equity¥3.6bnat 2022-12-31vCons.Net assets (5-year summary)
Net assets / equity¥4.3bnat 2021-12-31dCons.Net assets (5-year summary)
Cash and deposits¥517mat 2025-12-31Cons.Cash and deposits
Cash and deposits¥2.1bnat 2024-12-31Cons.Cash and deposits
Cash & equivalents¥517mat 2025-12-31Cons.Cash and cash equivalents
Cash & equivalents¥2.1bnat 2024-12-31Cons.Cash and cash equivalents
Cash & equivalents¥2.9bnat 2023-12-31vCons.Cash and cash equivalents
Cash & equivalents¥3.4bnat 2022-12-31vCons.Cash and cash equivalents (5-year summary)
Cash & equivalents¥3.8bnat 2021-12-31dCons.Cash and cash equivalents (5-year summary)
Operating cash flow−¥2.2bn2025-01-01 → 2025-12-31Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.4bn2024-01-01 → 2024-12-31Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.7bn2023-01-01 → 2023-12-31vCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥708m2022-01-01 → 2022-12-31vCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.5bn2021-01-01 → 2021-12-31dCons.Net cash provided by used in operating activities (5-year summary)
Investing cash flow−¥25m2025-01-01 → 2025-12-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥13m2024-01-01 → 2024-12-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥11m2023-01-01 → 2023-12-31vCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥126m2022-01-01 → 2022-12-31vCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥42m2021-01-01 → 2021-12-31dCons.Net cash provided by used in investing activities (5-year summary)
Financing cash flow¥605m2025-01-01 → 2025-12-31Cons.Net cash provided by used in financing activities
Financing cash flow¥567m2024-01-01 → 2024-12-31Cons.Net cash provided by used in financing activities
Financing cash flow¥1.2bn2023-01-01 → 2023-12-31vCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥367m2022-01-01 → 2022-12-31vCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.1bn2021-01-01 → 2021-12-31dCons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥-113.622025-01-01 → 2025-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-121.642024-01-01 → 2024-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-68.622023-01-01 → 2023-12-31vCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-99.12022-01-01 → 2022-12-31vCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-42.12021-01-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
Net assets per share¥16.16at 2025-12-31Cons.Net assets per share (5-year summary)
Net assets per share¥129.62at 2024-12-31Cons.Net assets per share (5-year summary)
Net assets per share¥226.16at 2023-12-31vCons.Net assets per share (5-year summary)
Net assets per share¥255.04at 2022-12-31vCons.Net assets per share (5-year summary)
Net assets per share¥323.54at 2021-12-31dCons.Net assets per share (5-year summary)
Equity ratio25.1%at 2025-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio89.3%at 2024-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio89.1%at 2023-12-31vCons.Equity to asset ratio (5-year summary)
Equity ratio85.0%at 2022-12-31vCons.Equity to asset ratio (5-year summary)
Equity ratio79.3%at 2021-12-31dCons.Equity to asset ratio (5-year summary)
Employees61at 2025-12-31Cons.Number of employees
Employees63at 2024-12-31Cons.Number of employees
Employees67at 2023-12-31vCons.Number of employees
Employees65at 2022-12-31vCons.Number of employees
Employees64at 2021-12-31dCons.Number of employees
Revenue¥491m2025-01-01 → 2025-12-31StandaloneNet sales
Revenue¥542m2024-01-01 → 2024-12-31StandaloneNet sales
Revenue¥1.5bn2023-01-01 → 2023-12-31vStandaloneNet sales (5-year summary)
Revenue¥1.2bn2022-01-01 → 2022-12-31vStandaloneNet sales (5-year summary)
Revenue¥1.9bn2021-01-01 → 2021-12-31dStandaloneNet sales (5-year summary)
Operating income−¥2.0bn2025-01-01 → 2025-12-31StandaloneOperating income
Operating income−¥2.1bn2024-01-01 → 2024-12-31StandaloneOperating income
Ordinary income−¥2.1bn2025-01-01 → 2025-12-31StandaloneOrdinary income
Ordinary income−¥2.1bn2024-01-01 → 2024-12-31StandaloneOrdinary income
Ordinary income−¥1.2bn2023-01-01 → 2023-12-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.4bn2022-01-01 → 2022-12-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥549m2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥2.1bn2025-01-01 → 2025-12-31StandaloneIncome before income taxes
Profit before tax−¥2.2bn2024-01-01 → 2024-12-31StandaloneIncome before income taxes
Net income−¥2.1bn2025-01-01 → 2025-12-31StandaloneProfit loss
Net income−¥2.2bn2024-01-01 → 2024-12-31StandaloneProfit loss
Net income−¥1.2bn2023-01-01 → 2023-12-31vStandaloneNet income loss (5-year summary)
Net income−¥1.4bn2022-01-01 → 2022-12-31vStandaloneNet income loss (5-year summary)
Net income−¥556m2021-01-01 → 2021-12-31dStandaloneNet income loss (5-year summary)
Total assets¥1.1bnat 2025-12-31StandaloneAssets
Total assets¥2.5bnat 2024-12-31StandaloneAssets
Total assets¥4.1bnat 2023-12-31vStandaloneTotal assets (5-year summary)
Total assets¥4.0bnat 2022-12-31vStandaloneTotal assets (5-year summary)
Total assets¥5.3bnat 2021-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥1.1bnat 2025-12-31StandaloneLiabilities
Total liabilities¥294mat 2024-12-31StandaloneLiabilities
Net assets / equity¥66mat 2025-12-31StandaloneNet assets
Net assets / equity¥2.2bnat 2024-12-31StandaloneNet assets
Net assets / equity¥3.6bnat 2023-12-31vStandaloneNet assets
Net assets / equity¥3.4bnat 2022-12-31vStandaloneNet assets (5-year summary)
Net assets / equity¥4.2bnat 2021-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥413mat 2025-12-31StandaloneCash and deposits
Cash and deposits¥1.8bnat 2024-12-31StandaloneCash and deposits
EPS (basic)¥-112.092025-01-01 → 2025-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-121.082024-01-01 → 2024-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-70.532023-01-01 → 2023-12-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-103.22022-01-01 → 2022-12-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-43.832021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥3.45at 2025-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥115.11at 2024-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥211.43at 2023-12-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥240.82at 2022-12-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥314.45at 2021-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio5.8%at 2025-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio88.2%at 2024-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio88.7%at 2023-12-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio84.6%at 2022-12-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio78.9%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued19,150,500at 2025-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued19,107,500at 2024-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued17,151,900at 2023-12-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued14,218,300at 2022-12-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued13,313,400at 2021-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees57at 2025-12-31StandaloneNumber of employees
Employees60at 2024-12-31StandaloneNumber of employees
Employees64at 2023-12-31vStandaloneNumber of employees
Employees62at 2022-12-31vStandaloneNumber of employees
Employees61at 2021-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 35
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment assetsat 2025-12-31¥528m
Drug Discovery Businessreportable segmentcapex2025-01-01 → 2025-12-31¥18m
Drug Discovery Businessreportable segmentemployeesat 2025-12-3133 pure
Drug Discovery Businessreportable segmentsegment assetsat 2025-12-31¥313m
Drug Discovery Businessreportable segmentsegment profit2025-01-01 → 2025-12-31−¥2.0bn
Drug Discovery Support Businessreportable segmentcapex2025-01-01 → 2025-12-31¥7m
Drug Discovery Support Businessreportable segmentemployeesat 2025-12-3120 pure
Drug Discovery Support Businessreportable segmentrevenue2025-01-01 → 2025-12-31¥579m
Drug Discovery Support Businessreportable segmentrevenue external2025-01-01 → 2025-12-31¥579m
Drug Discovery Support Businessreportable segmentsegment assetsat 2025-12-31¥388m
Drug Discovery Support Businessreportable segmentsegment profit2025-01-01 → 2025-12-31−¥51m
—segment totalcapex2025-01-01 → 2025-12-31¥25m
—segment totalrevenue2025-01-01 → 2025-12-31¥579m
—segment totalrevenue external2025-01-01 → 2025-12-31¥579m
—segment totalsegment assetsat 2025-12-31¥701m
—segment totalsegment profit2025-01-01 → 2025-12-31−¥2.1bn
Reconciling Itemsreconcilingsegment assetsat 2024-12-31¥1.9bn
Drug Discovery Businessreportable segmentcapex2024-01-01 → 2024-12-31¥9m
Drug Discovery Businessreportable segmentdepreciation2024-01-01 → 2024-12-31¥8m
Drug Discovery Businessreportable segmentsegment assetsat 2024-12-31¥291m
Drug Discovery Businessreportable segmentsegment profit2024-01-01 → 2024-12-31−¥2.0bn
Drug Discovery Support Businessreportable segmentcapex2024-01-01 → 2024-12-31¥9m
Drug Discovery Support Businessreportable segmentdepreciation2024-01-01 → 2024-12-31¥23m
Drug Discovery Support Businessreportable segmentrevenue2024-01-01 → 2024-12-31¥636m
Drug Discovery Support Businessreportable segmentrevenue external2024-01-01 → 2024-12-31¥636m
Drug Discovery Support Businessreportable segmentsegment assetsat 2024-12-31¥566m
Drug Discovery Support Businessreportable segmentsegment profit2024-01-01 → 2024-12-31−¥34m
—segment totalcapex2024-01-01 → 2024-12-31¥18m
—segment totaldepreciation2024-01-01 → 2024-12-31¥31m
—segment totalrevenue2024-01-01 → 2024-12-31¥636m
—segment totalrevenue external2024-01-01 → 2024-12-31¥636m
—segment totalsegment assetsat 2024-12-31¥857m
—segment totalsegment profit2024-01-01 → 2024-12-31−¥2.1bn
Drug Discovery Businessreportable segmentemployeesat 2025-12-3132 pure
Drug Discovery Support Businessreportable segmentemployeesat 2025-12-3117 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,288
ItemContextValueUnit
Issuance of new sharesCurrentYearDuration_NonConsolidatedMember9692000JPY
Capital reductionCurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember－JPY
Capital reductionCurrentYearDuration_NonConsolidatedMember－JPY
Deficit dispositionCurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember－JPY
Deficit dispositionCurrentYearDuration_NonConsolidatedMember－JPY
Profit lossCurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember-2142272000JPY
Profit lossCurrentYearDuration_NonConsolidatedMember-2142272000JPY
Purchase of treasury stockCurrentYearDuration_NonConsolidatedMember_TreasuryStockMember-5000JPY
Purchase of treasury stockCurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember-5000JPY
Purchase of treasury stockCurrentYearDuration_NonConsolidatedMember-5000JPY
Net changes of items other than shareholders equityCurrentYearDuration_NonConsolidatedMember_ValuationDifferenceOnAvailableForSaleSecuritiesMember568000JPY
Net changes of items other than shareholders equityCurrentYearDuration_NonConsolidatedMember_ValuationAndTranslationAdjustmentsMember568000JPY
Net changes of items other than shareholders equityCurrentYearDuration_NonConsolidatedMember568000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_TreasuryStockMember-5000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember-2132585000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_ValuationDifferenceOnAvailableForSaleSecuritiesMember568000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember_ValuationAndTranslationAdjustmentsMember568000JPY
Total changes of items during the periodCurrentYearDuration_NonConsolidatedMember-2132017000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_TreasuryStockMember-227000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_ShareholdersEquityMember68970000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_ValuationDifferenceOnAvailableForSaleSecuritiesMember-2862000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember_ValuationAndTranslationAdjustmentsMember-2862000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember66108000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember1886906000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember1851353000JPY
Depreciation sgaPrior1YearDuration_NonConsolidatedMember2918000JPY
Depreciation sgaCurrentYearDuration_NonConsolidatedMember－JPY
Commission fee sgaPrior1YearDuration_NonConsolidatedMember119195000JPY
Commission fee sgaCurrentYearDuration_NonConsolidatedMember119187000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第1項
Place of filing cover pageFilingDateInstant
Original text (Japanese)近畿財務局長
Filing date cover pageFilingDateInstant2026-03-26
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第23期(自　2025年1月1日　至　2025年12月31日)
Company name cover pageFilingDateInstant
Original text (Japanese)カルナバイオサイエンス株式会社
Company name in english cover pageFilingDateInstantCarna Biosciences, Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　吉野公一郎
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)神戸市中央区港島南町一丁目5番5号
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)078-302-7039(代表)
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)取締役経営管理本部長　山本詠美
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)神戸市中央区港島南町一丁目5番5号
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)078-302-7039(代表)
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)取締役経営管理本部長　山本詠美
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE00987
Fund codeFilingDateInstant－
Security codeFilingDateInstant45720
Filer name in japaneseFilingDateInstant
Original text (Japanese)カルナバイオサイエンス株式会社
Filer name in englishFilingDateInstantCarna Biosciences, Inc.
Fund name in japaneseFilingDateInstant－

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed
balance sheet identityconsolidated 2024-12-31pass rounding
balance sheet identityconsolidated 2025-12-31pass rounding
balance sheet identitynon_consolidated 2024-12-31pass rounding
balance sheet identitynon_consolidated 2025-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net assetsconsolidated 2024-12-31pass
statement vs summary · net assetsconsolidated 2025-12-31pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · net assetsnon_consolidated 2024-12-31pass
statement vs summary · net assetsnon_consolidated 2025-12-31pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-12-31pass
statement vs summary · net income attributable to parentconsolidated 2025-01-01/2025-12-31pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-12-31pass
statement vs summary · operating cash flowconsolidated 2025-01-01/2025-12-31pass
statement vs summary · revenueconsolidated 2024-01-01/2024-12-31pass
statement vs summary · revenueconsolidated 2025-01-01/2025-12-31pass
statement vs summary · revenuenon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · revenuenon_consolidated 2025-01-01/2025-12-31pass
statement vs summary · total assetsconsolidated 2024-12-31pass
statement vs summary · total assetsconsolidated 2025-12-31pass
statement vs summary · total assetsnon_consolidated 2024-12-31pass
statement vs summary · total assetsnon_consolidated 2025-12-31pass